Загрузка...

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Histone deacetylase inhibitors (HDACi) have proven activity in hematologic malignancies, and their FDA approval in multiple myeloma (MM) and T-cell lymphoma highlights the need for further development of this drug class. We investigated AR-42, an oral pan-HDACi, in a first-in-man phase 1 dose escala...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Leuk Lymphoma
Главные авторы: Sborov, Douglas W., Canella, Alessandro, Hade, Erinn M., Mo, Xiaokui, Khountham, Soun, Wang, Jiang, Ni, Wenjun, Poi, Ming, Coss, Christopher, Liu, Zhongfa, Phelps, Mitch A., Mortazavi, Amir, Andritsos, Leslie, Baiocchi, Robert A., Christian, Beth A, Benson, Don M., Flynn, Joseph, Porcu, Pierluigi, Byrd, John C., Pichiorri, Flavia, Hofmeister, Craig C.
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5489371/
https://ncbi.nlm.nih.gov/pubmed/28270022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1298751
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!